{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:58:41Z","timestamp":1790740721823,"version":"4.1.0"},"reference-count":30,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T00:00:00Z","timestamp":1692921600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The fixed dose combination of calcipotriene (CAL) and betamethasone dipropionate (BDP) is a well\u2010established topical treatment option for psoriasis based on strong scientific rationale for the single agents having complementary efficacy and safety. CAL\/BDP PAD\u2010cream is an easily spreadable cream based on PAD Technology\u2122, an innovative formulation and drug delivery system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives and Methods<\/jats:title>\n                    <jats:p>A Phase 3, multicentre, randomized, investigator\u2010blind, active and vehicle\u2010controlled trial enrolling 490 patients with mild to moderate psoriasis according to the Physician Global Assessment (PGA) scale was conducted in three European countries. Products were applied once daily for 8\u2009weeks. The aim of the trial was to evaluate the efficacy and safety of CAL\/BDP PAD\u2010cream as well as treatment acceptability compared to CAL\/BDP gel and PAD\u2010cream vehicle. Primary endpoint was percentage change in modified Psoriasis Area and Severity Index (mPASI) from baseline to Week 8.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The percentage mean change from baseline to Week 8 in mPASI for CAL\/BDP PAD\u2010cream (67.5%) was superior compared to PAD\u2010cream vehicle (11.7%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001) and non\u2010inferior to CAL\/BDP gel (63.5%). The proportion of patients achieving PGA treatment success (at least two\u2010step improvement to clear or almost clear) after 8\u2009weeks was superior for CAL\/BDP PAD\u2010cream (50.7%) compared to PAD\u2010cream vehicle (6.1%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001) and statistically significantly greater than CAL\/BDP gel (42.7%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0442). Patient\u2010reported psoriasis treatment convenience score (PTCS) for CAL\/BDP PAD\u2010cream was rated superior to CAL\/BDP gel at Week 8 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001) and the mean change in DLQI from baseline to Week 8 improved statistically significantly more in the CAL\/BDP PAD\u2010cream group compared to both PAD\u2010cream vehicle (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001) and CAL\/BDP gel (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0110). Safety assessments during the trial demonstrated that CAL\/BDP PAD\u2010cream was well\u2010tolerated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>CAL\/BDP PAD\u2010cream is a novel topical treatment of psoriasis that has a high efficacy and a favourable safety profile combined with a superior patient\u2010reported treatment convenience.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jdv.19330","type":"journal-article","created":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T09:20:36Z","timestamp":1689067236000},"page":"2327-2335","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Randomized Phase 3 trial demonstrating high efficacy, favourable safety and convenience of a novel calcipotriol and betamethasone dipropionate cream for the treatment of psoriasis"],"prefix":"10.1111","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1330-1502","authenticated-orcid":false,"given":"A.","family":"Pinter","sequence":"first","affiliation":[{"name":"Department of Dermatology University Hospital Frankfurt am Main  Frankfurt am Main Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Reich","sequence":"additional","affiliation":[{"name":"Department of Dermatology University of Rzeszow  Rzesz\u00f3w Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7919-9619","authenticated-orcid":false,"given":"P.","family":"Arenberger","sequence":"additional","affiliation":[{"name":"Charles University  Prague Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2758-1605","authenticated-orcid":false,"given":"L. S.","family":"Gold","sequence":"additional","affiliation":[{"name":"Dermatology Clinical Research Henry Ford Health System  Detroit Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Armstrong","sequence":"additional","affiliation":[{"name":"University of Southern California  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Iversen","sequence":"additional","affiliation":[{"name":"MC2 Therapeutics  H\u00f8rsholm Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Praestegaard","sequence":"additional","affiliation":[{"name":"MC2 Therapeutics  H\u00f8rsholm Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4026-8728","authenticated-orcid":false,"given":"M.","family":"Augustin","sequence":"additional","affiliation":[{"name":"University Medical Center Hamburg\u2010Eppendorf  Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,8,25]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1590"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12549"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00635-4"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.7326\/AITC201804030"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12443"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2012.04518.x"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.2310\/7750.2011.10066"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.07.087"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032713-120225"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.07.004"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2015.12.009"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12444"},{"issue":"8","key":"e_1_2_11_14_1","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/ddg.12396","article-title":"Topical long\u2010term therapy of psoriasis with vitamin D(3) analogues, corticosteroids and their two compound formulations: position paper on evidence and use in daily practice","volume":"12","author":"Augustin M","year":"2014","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S1478"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2010.541005"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1159\/000096069"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1081\/DDC-200040297"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2005.01329.x"},{"issue":"1","key":"e_1_2_11_20_1","first-page":"46","article-title":"Assessing attributes of topical vehicles for the treatment of acne, atopic dermatitis, and plaque psoriasis","volume":"94","author":"Eastman WJ","year":"2014","journal-title":"Cutis"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/srt.12307"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00794-y"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00626-5"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.5653"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17734"},{"key":"e_1_2_11_26_1","unstructured":"Wynzora Summary of Product Characteristics. Last updtaed 2022."},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18333"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3245"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1746734"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.04060.x"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.7372"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.19330","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T09:17:17Z","timestamp":1698225437000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.19330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,25]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.1111\/jdv.19330"],"URL":"https:\/\/doi.org\/10.1111\/jdv.19330","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,25]]},"assertion":[{"value":"2023-02-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}